Zoetis Inc. $ZTS Stake Lifted by Profund Advisors LLC

Profund Advisors LLC grew its stake in shares of Zoetis Inc. (NYSE:ZTS) by 226.7% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 25,433 shares of the company’s stock after acquiring an additional 17,649 shares during the period. Profund Advisors LLC’s holdings in Zoetis were worth $1,776,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Wealthfront Advisers LLC boosted its holdings in Zoetis by 80.2% in the 2nd quarter. Wealthfront Advisers LLC now owns 76,113 shares of the company’s stock worth $5,469,000 after buying an additional 33,873 shares during the period. Pacer Advisors Inc. raised its holdings in Zoetis by 16.7% during the 1st quarter. Pacer Advisors Inc. now owns 165,570 shares of the company’s stock valued at $19,572,000 after acquiring an additional 23,687 shares during the period. Diamond Hill Capital Management LLC Investment Advisor raised its holdings in Zoetis by 21.5% during the 2nd quarter. Diamond Hill Capital Management LLC Investment Advisor now owns 3,557,436 shares of the company’s stock valued at $255,637,000 after acquiring an additional 629,974 shares during the period. Swedbank AB raised its holdings in Zoetis by 9.9% during the 1st quarter. Swedbank AB now owns 3,004,200 shares of the company’s stock valued at $355,126,000 after acquiring an additional 269,610 shares during the period. Finally, Munich Reinsurance Co Stock Corp in Munich lifted its position in shares of Zoetis by 2,448.6% during the first quarter. Munich Reinsurance Co Stock Corp in Munich now owns 23,804 shares of the company’s stock worth $2,814,000 after acquiring an additional 22,870 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on ZTS shares. The Goldman Sachs Group began coverage on Zoetis in a report on Friday, October 16th. They issued a “neutral” rating and a $74.00 price target for the company. Cantor Fitzgerald set a $94.00 price objective on Zoetis in a research note on Tuesday, August 25th. HSBC decreased their price objective on Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. Piper Sandler dropped their price objective on Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a report on Monday, August 10th. Finally, TD Cowen cut their target price on Zoetis from $104.00 to $94.00 and set a “buy” rating for the company in a research note on Tuesday, August 25th. Six investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Zoetis presently has a consensus rating of “Hold” and a consensus target price of $93.79.

Zoetis Stock Up 4.3%

ZTS opened at $83.18 on Tuesday. The firm has a market capitalization of $34.37 billion, a P/E ratio of 11.82, a price-to-earnings-growth ratio of 1.15 and a beta of 0.74. Zoetis Inc. has a one year low of $68.77 and a one year high of $144.83. The company has a fifty day moving average price of $75.15 and a 200-day moving average price of $93.43. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. The company had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%. The firm’s revenue was down .2% compared to the same quarter last year. During the same quarter last year, the business posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities research analysts expect that Zoetis Inc. will post 6.15 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Friday, October 30th. Zoetis’s dividend payout ratio is 34.93%.

Zoetis Company Profile

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.